Natera Inc. (NTRA)
NASDAQ: NTRA
· Real-Time Price · USD
170.38
3.03 (1.81%)
At close: Oct 06, 2025, 3:59 PM
166.60
-2.22%
After-hours: Oct 06, 2025, 07:55 PM EDT
1.81% (1D)
| Bid | 164.02 |
| Market Cap | 23.38B |
| Revenue (ttm) | 1.96B |
| Net Income (ttm) | -253.24M |
| EPS (ttm) | -1.91 |
| PE Ratio (ttm) | -89.2 |
| Forward PE | -174.32 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 170.41 |
| Volume | 1,251,821 |
| Avg. Volume (20D) | 1,304,300.4 |
| Open | 167.36 |
| Previous Close | 167.35 |
| Day's Range | 167.22 - 172.68 |
| 52-Week Range | 117.27 - 183.00 |
| Beta | 1.74 |
| Ex-Dividend Date | n/a |
About NTRA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NTRA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NTRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNatera Inc. is scheduled to release its earnings on
Nov 11, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+3.35%
Natera shares are trading higher after Piper Sandl...
Unlock content with
Pro Subscription
2 months ago
+7.7%
Natera shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY25 sales guidance above estimates.
6 days ago · businesswire.com
Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPTAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollmen...
1 month ago · seekingalpha.com
Natera: A Buy As Positive Growth And Cashflow Outweigh UnprofitabilityFor my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers...
